Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
August 2025
The global infectious diseases market size reached USD 21.74 billion in 2024, grew to USD 23 billion in 2025, and is projected to hit around USD 38.19 billion by 2034, expanding at a CAGR of 5.8% during the forecast period from 2025 to 2034.
Infectious diseases like malaria, tuberculosis, influenza, HIV/ AIDS, fungal infections, and many other deadly infections continue to rise and impact the global population. With vaccine developments, climate change, and antimicrobial resistance, people are becoming more aware of their health and cleanliness. Modern technologies like next-generation sequencing and PCR help researchers of infectious diseases to bring novel therapeutic solutions in front of the nation.
| Table | Scope |
| Market Size in 2025 | USD 23 Billion |
| Projected Market Size in 2034 | USD 38.19 Billion |
| CAGR (2025 - 2034) | 5.8% |
| Leading Region | North America Share 38% |
| Market Segmentation | By Product / Solution, By Therapeutic Area / Pathogen Focus, By Therapeutic Area / Pathogen Focus, By Technology / Modality, By End User / Customer, By Distribution Channel & Commercial Model, By Region |
| Top Key Players | Pfizer, GlaxoSmithKline, Sanofi Pasteur, Moderna, Johnson & Johnson, Merck & Co., AstraZeneca, Novavax, Gilead Sciences, Roche Diagnostics, Abbott Laboratories, Thermo Fisher Scientific, bioMérieux, BD (Becton, Dickinson & Co.), Qiagen, Hologic, Seqirus / CSL, Takeda Pharmaceutical, Lonza / Catalent, WHO / Gavi / UNICEF |
The infectious diseases market covers the prevention, diagnosis, treatment, and surveillance of diseases caused by pathogens such as bacteria, viruses, fungi, and parasites. It includes vaccines, anti-infective therapeutics (antibiotics, antivirals, antifungals, antiparasitics), biologics (monoclonal antibodies, immunotherapies), diagnostics (molecular, serology, rapid antigen tests, culture & susceptibility), and enabling services (CROs, CDMOs, public-health surveillance, antimicrobial stewardship programs). The huge demand for all these services and solutions is driven by endemic and pandemic disease burdens, antimicrobial resistance (AMR), vaccine campaigns, diagnostic-led treatment, expanding point-of-care testing, and sustained investments in novel antivirals, vaccines, and diagnostics.
By considering the global health disparities, world leaders are contributing to advanced immunization efforts. For instance, in June 2025, Gavi, the Vaccine Alliance, secured more than US$9 billion in support from world leaders at the Global Summit: Health and Prosperity through Immunization held in Brussels over the next 5 years of its strategic period from 2026-2030.
There are numerous developments in vaccines for human trials to ensure the safety and efficacy of vaccines. For instance, in July 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) announced it was providing US$17.3 million to Public Health Vaccines to advance its Nipah vaccine through early-stage clinical testing.
Artificial intelligence plays a significant role in the early diagnosis and treatment of infectious diseases. The accuracy and efficiency of disease detection and surveillance are enhanced by AI-driven diagnostic tools, deep learning, machine learning algorithms, and image recognition systems. AI accelerates the drug discovery and development process and predicts disease outbreaks. It also optimizes treatment strategies and enables personalized interventions.
What are the Major Drifts in the Infectious Diseases Market?
With significant climate changes, the spread of infectious diseases like dengue is also increasing among different communities. The various bacterial species are becoming resistant to antibiotics and related treatments to cure infections caused by them, which introduces antimicrobial resistance. The vaccine design and development efforts are on the rise, along with the notable decline in the costs of vaccines and vaccine immunization plans.
What are the Potential Challenges in the Infectious Diseases Market?
North America and South America are facing a high rate of infectious diseases, and this number is continuing to rise. A notable increase in some other new infections is seen in Sub-Saharan Africa. Certain challenges remain despite improvements in HIV/ AIDS treatments. Most of the population remains underserved by many HIV programs due to low socioeconomic status, lack of education, poverty, and inadequate HIV prevention investments.
What is the Future of the Infectious Diseases Market?
There are certain improvements in HIV/ AIDS treatments and the global response to it. The antiretroviral therapy is proving to save millions of lives of people from AIDS and reduce AIDS-related deaths. International conferences on contagious diseases keep an eye on novel strategies in research and treatments. In October 2025, the 4th International Conference on Infectious Diseases will be held in Dubai, UAE, to unite several researchers and healthcare professionals to share their knowledge about the latest advancements in research and innovations.
The therapeutics segment dominated the market in 2024, owing to the major role of therapeutics in the prevention, control, and treatment of numerous infections. The therapeutic effects enable personalized care, minimize side effects, and improve patient outcomes. The various therapeutic approaches, such as immunotherapies, monoclonal antibodies, targeted therapies, and vaccines, are essential to prevent contagious diseases and activate long-term immune memory.
The vaccines segment is expected to grow at the fastest CAGR in the market during the forecast period due to the significance of vaccinations to protect the global population, especially vulnerable individuals. Vaccines reduce disease severity and avoid long-term complications. Vaccine immunization prevents infection-related cancers and provides herd immunity.
The respiratory & viral segment dominated the market in 2024, owing to the benefits of respiratory therapy and viral therapeutics. They facilitate airway clearance, ventilation, oxygen therapy, and pulmonary drug delivery. Viral therapeutics manage systemic responses to infections and enable targeted treatments through monoclonal antibodies.
The tropical & parasitic diseases segment is expected to grow at the fastest CAGR in the market during the predicted timeframe due to the therapeutic benefits in balancing the immune response and inducing regulatory cells. Therapeutics related to tropical and parasitic diseases contribute to curing inflammatory and autoimmune diseases. This therapeutic area also serves to treat asthma, allergies, multiple sclerosis, inflammatory bowel disease, metabolic disorders, and other health conditions.
The small-molecule drugs & generic antimicrobials segment dominated the market in 2024, owing to their major role in intracellular targeting and infectious disease management. These medicinal drugs and generics reduce costs, increase accessibility, improve convenience, and elicit effective treatments. They are easy for oral administration and deliver precision in patient care.
The vaccines segment is expected to grow at the fastest CAGR in the market during the forecast period due to the importance of vaccination to reduce disease severity, prevent diseases, and provide long-term immunity. Vaccines provide global and economic benefits in terms of economic productivity and global health security. Vaccine immunization presents reduced antimicrobial resistance and maintenance of healthcare capacity.
The hospitals & acute care segment dominated the market in 2024, owing to the pivotal role of hospitals and acute care for patients in clinical data management, diagnosis, and treatments. They also contribute to the control and prevention of infections, surveillance, and public health. Hospitals make efforts to advance training and education on contagious diseases for healthcare staff through different research initiatives.
The clinical & reference laboratories segment is expected to grow at the fastest CAGR in the market during the predicted timeframe due to the prominent role of clinical laboratories in the rapid identification of pathogens and antimicrobial susceptibility testing. They provide point-of-care testing, control infections, and manage patients. They are vital in R&D, confirmatory testing, and emergency response.
The hospital/institutional procurement & GPOs segment dominated the market in 2024, owing to the major role of hospitals in delivering proactive strategies for daily infection control and reactive strategies for managing disease outbreaks. The group purchasing organizations collaborate with multiple healthcare providers to achieve market stability and standardize best practices. The GPOs introduce increased purchasing power along with data and market intelligence.
The online/telehealth prescribing & home-testing segment is expected to grow at the fastest CAGR in the market during the forecast period due to improved patient convenience and patient engagement. These services enable improved access to care and rapid responses to outbreaks. Telehealth prescribing and home-testing are related to HIV, TB, sexually transmitted infections, hepatitis C, and some other health conditions.
North America dominated the infectious diseases market share 38% in 2024 owing to strong R&D investments, advanced diagnostic tools, and favorable laboratory networks. In March 2025, the World Health Organization (WHO) reported about the disease outbreak of measles in the United States of America, for which the US CDC and other government agencies put their efforts to control the outbreak of the disease in the country.
The National Foundation for Infectious Diseases (NFID) conducted a national survey to identify the attitudes and behavior of US adults towards vaccination. The U.S. National Science Foundation (NSF) introduced the Ecology and Evolution of Infectious Diseases program (EEID) to support research on infectious diseases at the ecological, evolutionary, social, and organismal levels.
In March 2025, the Board of Executive Directors of the World Bank launched the One Health project to accelerate health resilience in Guyana with the investment of US$ 22-million to empower the country to prevent, prepare, and respond to health emergencies.
The U.S. Centers for Disease Control and Prevention (CDC) has set its global health strategic framework for 2024 to advance data and surveillance, laboratory capabilities, workforce and institutions, and research and innovation. It aims to create strong public health systems, provide technical assistance, and share expertise. The CDC plays a pivotal role in protecting the U.S. by strengthening global preparedness for any health emergency in the future.
Health Canada protects Canadians from unsafe food and consumer products to protect their health. Canada has a good presence of several supporting organizations, like the Public Health Agency of Canada (PHAC), Canadian Food Inspection Agency (CFIA), and Health Canada (HC), which are responsible for helping Canadians maintain and improve their health. There is strong support for research, science, and the healthcare system of Canada.
The Asia Pacific is estimated to host the fastest-growing infectious diseases market during the forecast period. This regional growth is attributed to expanding immunization programs, rising diagnostic capacity, growing local manufacturing, and access initiatives. In November 2025, the Asia Pacific Congress of Clinical Microbiology & Infection (APCCMI) will be held in Bangkok, Thailand.
The 5th World Sepsis Congress was introduced by the Global Sepsis Alliance in April 2025 to address the impact of climate change on infectious diseases, the rising concern of antimicrobial resistance, and strategies to overcome these disparities. The World Health Organization runs the joint infectious diseases unit and also launched the TB-free Central Asia initiative in July 2025. The grant fund created by the International Pathogen Surveillance Network in November 2024 for 10 research projects was hosted by the United Nations Foundation and supported by the Rockefeller Foundation, Bill & Melinda Gates Foundation, and Wellcome.
In November 2024, the International Pathogen Surveillance Network established a grant fund to support 10 projects of the WHO and partners with US$2 million in grants to better understand disease threats and improve capacities in pathogen genomic surveillance.
The R&D process for infectious diseases involves discovery, preclinical research, clinical development, regulatory review, approval, manufacturing, and post-marketing surveillance.
Key Players: Roche, GlaxoSmithKline, Johnson & Johnson, Sanofi, Pfizer.
Clinical trial phases for infectious diseases include phase I, phase II, phase III, and phase IV trials that focus on the safety, efficacy, and post-marketing surveillance. Moreover, the major regulatory agencies across the U.S., India, the WHO, and Europe contribute to the regulatory approvals.
Key Players: Moderna and BioNTech, Merck & Co., Bavarian Nordic, Vir Biotechnology, and Sanofi.
The various interventions, disease-specific education, patient and family resources, advocacy, and counselling are integral parts of patient support and services for people.
Key Players: Novartis, AstraZeneca, AbbVie, Merck, Pfizer.
In October 2024, Annaliesa Anderson, Ph.D., Senior Vice President and Head, Vaccine Research and Development, Pfizer, declared that Pfizer remains prominent for vaccine and therapeutic development in respiratory and infectious diseases. She also proclaimed that IDWeek 2024 stands as an exclusive platform to introduce Pfizers innovative advancements and interact with the scientific community due to the effective work of Pfizer to tackle challenges posed by infectious diseases.
By Product / Solution
By Therapeutic Area / Pathogen Focus
By Technology / Modality
By End User / Customer
By Distribution Channel & Commercial Model
By Region
August 2025
August 2025
August 2025
August 2025